Search Results for "scopolamine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for scopolamine. Results 1 to 3 of 3 total matches.

In Brief: Hyperthermia with Scopolamine Patches

   
The Medical Letter on Drugs and Therapeutics • Jun 30, 2025  (Issue 5114)
In Brief: Hyperthermia with Scopolamine Patches ...
The FDA has required a new warning in the label for the scopolamine transdermal patch (Transderm-Scōp, and generics) about a risk of serious or fatal hyperthermia. Scopolamine, an anticholinergic drug, is FDA-approved for prevention of nausea and vomiting associated with motion sickness or recovery after surgery in adults; it is often used off-label to reduce drooling in children and adolescents with neurologic disorders.
Med Lett Drugs Ther. 2025 Jun 30;67(5114):1   doi:10.58347/tml.2025.5114a |  Show IntroductionHide Introduction

Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
, and the scopolamine patch can reduce nausea and vomiting, but trials evaluating their efficacy for treatment ...
The FDA has approved Gimoti (Evoke), a nasal spray formulation of the dopamine-2 (D2) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide (Reglan, and generics) has been available for years in conventional and orally-disintegrating tablets and in an injectable formulation. It is the only drug that is FDA-approved for treatment of diabetic gastroparesis.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):5-7 |  Show IntroductionHide Introduction

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
Anticholinergic Scopolamine – generic 1 mg patches 1 patch evening before surgery Keep patch on for 2 days $17.60 ...
The FDA has approved IV amisulpride (Barhemsys – Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):205-8 |  Show IntroductionHide Introduction